Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company, has successfully completed a public offering of $287.5 million in Convertible Senior Notes, with the full exercise of the Greenshoe option resulting in an additional $37.5 million. This transaction was announced on July 6, 2026, and is aimed at bolstering the company's financial position to support its ongoing initiatives in cancer treatment.

The offering consisted of 0.75% Convertible Senior Notes due 2032, which were sold under a registration statement that became effective in March 2025. The exercise of the Greenshoe option allowed underwriters to purchase additional notes, bringing the total proceeds to approximately $277.6 million after accounting for underwriting discounts and estimated expenses. Nuvation Bio plans to utilize these proceeds for general corporate purposes, including working capital and operational expenditures, which are critical for advancing its diverse pipeline of oncology therapies.

Nuvation Bio is focused on addressing significant challenges in cancer treatment, with a pipeline that includes innovative therapies such as taletrectinib, a next-generation ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor. The company’s strategic emphasis on developing impactful therapies positions it well within the competitive oncology sector, which has seen increased investment and innovation in recent years. The successful completion of this financing round enhances Nuvation Bio's ability to execute its research and development strategies effectively.

The exercise of the Greenshoe option reflects strong demand for Nuvation Bio’s offerings and indicates investor confidence in the company's future prospects. The capped call transactions associated with this offering, which set a cap price significantly above the recent trading price of the company's stock, further demonstrates a strategic approach to managing dilution and optimizing capital structure.

As the oncology sector continues to evolve with new therapies and technologies, Nuvation Bio's recent capital raise positions it to capitalize on growth opportunities while navigating the complexities of drug development and commercialization. The broader implications of this transaction may signal a favorable outlook for similar companies in the oncology space, as access to capital remains crucial for advancing innovative treatments in a highly competitive market.